Replies to post #235038 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Well, this is what Les Francais had to say:-

With a cost of €21 000 per month and a median of 9 months of treatment, TTF therapy would be one of the most expensive treatments using a medical device. A price halved by 2 would still exceed conventional benchmarks (€292 353/LYG). A decrease of monthly price to €3000 per month would lead to a more acceptable ICER.

To our knowledge, no data from the EF-14 trial are currently available to compare the clinical outcome of patients who continued TTF therapy after the first progression with those who discontinued after the first progression. Hence, the impact on the ICER of early TTF therapy discontinuation after the first progression cannot be measured.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933490/

Maybe the Germans are less discerning about value for money.